• Increase font size
  • Default font size
  • Decrease font size

Flanders Names Tom Justice Chief Operating Officer

Print E-mail
Tuesday, 14 July 2009 08:27

WASHINGTON, NC-- Flanders Corporation (NASDAQ: FLDR) has appointed industry veteran Tom Justice, 56, as its new Chief Operating Officer.

Harry Smith, CEO and Chairman of the Board, stated, "We are very pleased to have Tom join Flanders. A 28-year veteran of the air filtration industry, Tom brings tremendous experience in operations management and product development. He will play an integral role in our efforts to grow revenue and improve profitability, strengthening our ability to achieve operational excellence and to develop innovative new products."

A leader in the air filtration industry, Justice serves on several industry related technical committees, including the Underwriters Lab Standards Technical Panel for UL 900. He is also a member of ASHRAE, NAFA and the American Filtration Society.

Justice most recently served as Senior Applications Engineer in the Engineered Products Division of Johns Manville. Prior to joining Johns Manville in December 2007, he consulted with various companies in the air filtration industry, including Flanders, after having served 24 years at Purolator (later Clarcor Air Filtration) in several roles including plant manager, Director of Engineering and VP of Operations. Justice earned his B.S. in Mechanical Engineering from N.C. State University.

About Flanders

Flanders is a leading air filtration products manufacturer. Flanders' products are utilized by many industries, including those associated with commercial and residential heating, ventilation and air conditioning systems, semiconductor manufacturing, ultra-pure materials, biotechnology, pharmaceuticals, synthetics, nuclear power and nuclear materials processing. For further information on Flanders and its products, visit its web site at http://www.flanderscorp.com/ or contact Kirsten Chapman or Tim Dien at (415) 433-3777.




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 8 hours ago Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data: Below i... http://t.co/IbLYNqgb
about 16 hours ago Shares of $IDIX drop slightly after compelling new data from rival Gilead ($GILD) puts prospects for IDIX's hepatitis C drug in question.
about 1 day ago Medgenics has Key to Protein Therapy Market: Medgenics (NASDAQ: MDGN) has what I believe to be the most disrupti... http://t.co/c3IBIWYR
about 1 day ago Stocks Vacillate To Mixed Finish; Some Leaders Rally http://t.co/dtOQTRgh
about 1 day ago Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR: Belo... http://t.co/a7IlIvbS
about 1 day ago Athersys $ATHX gets grant to study traumatic brain injury http://t.co/mnZTsxXx
about 1 day ago Watching: San Antonio patients help test new 'spray-on skin' for burns http://t.co/fzKA9B23
about 1 day ago OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012: During the past few sessi... http://t.co/fKOMc1TM

navigation

Free Phone Trade Alerts